Figure 3
From: MicroRNA-223 is a novel negative regulator of HSP90B1 in CLL
Kaplan-Meier plot of time to first therapy of CLL patients according toHSP90B1expression. Patients overexpressing HSP90B1 (green line) had a significantly shorter TFT (median = 17 months; 95%CI: 5–28.9 months) as compared to that of patients with lower HSP90B1 expression levels (blue line) (median = 104 months, P = 0.024).